 |
|
Adrenal Function in the Human Immunodeficiency Virus–Infected Patient
Jose Mayo, MD;
Julio Collazos, MD;
Eduardo Martínez, MD;
Sofía Ibarra, MD
Arch Intern Med. 2002;162:1095-1098.
ABSTRACT
| |
Although clinical manifestations of adrenal dysfunction are uncommon
in patients infected with human immunodeficiency virus (HIV), subclinical
functional abnormalities of the hypothalamic-pituitary-adrenal axis are frequent.
Patients infected with HIV usually have higher basal serum cortisol and lower
serum dehydroepiandrosterone concentrations than HIV-seronegative individuals.
This imbalance has been related to progression of the infection by inducing
a shift from TH1 to TH2 immunologic responses. Although,
adrenal reserve may be marginal in HIV-infected patients, clinically evident
adrenal insufficiency is uncommon and, when present, it is observed in advanced
stages of the infection. Hypocortisolemia should be treated regardless of
the existence of associated symptoms. On the contrary, hypercortisolemia in
the absence of features of Cushing syndrome is common and should not promote
treatment nor specific studies. The possible influence that alterations of
the adrenal function could have on the patients' immune status and the eventual
effect of antiretrovirals on these alterations merit further investigation.
INTRODUCTION
Adrenal gland involvement has been documented in as many as two thirds
of patients with acquired immunodeficiency syndrome (AIDS) at postmortem examination.1 However, adrenal insufficiency is seldom diagnosed
in clinical practice because symptoms do not appear until more than 80% of
the gland has been destroyed, and the extent of necrosis in the most frequent
autopsy finding, cytomegalovirus adrenalitis, rarely exceeds 60%.2-3 Nevertheless, 2 (3%) of 75 autopsies
performed in unselected patients with AIDS at a single center revealed greater
than 80% destruction of the adrenal cortex by cytomegalovirus4;
this is in agreement with the 3% of patients who had an antemortem diagnosis
of adrenal insufficiency in another necropsy series.1
Less common pathological processes include other opportunistic infections
(Mycobacterium tuberculosis and Mycobacterium avium–intracellulare, Cryptococcus neoformans, Histoplasma
capsulatum, Pneumocystis carinii, and Toxoplasma
gondii), neoplasms (Kaposi sarcoma and lymphoma), hemorrhage, fibrosis,
infarction, and more subtle abnormalities such as cortical lipid depletion,
a likely surrogate of long-lasting severe stress.2-3,5-6
Adrenocortical antibodies are detected in a substantial proportion of patients
with AIDS,3, 5 probably as an epiphenomenon
linked to nonspecific B-cell activation and devoid of clinical significance.
Finally, several drugs have been found to be responsible for adrenal insufficiency
by decreasing steroidogenesis (ketoconazole), enhancing cortisol metabolism
(rifampin), or suppressing pituitary secretion of corticotropin due to their
intrinsic glucocorticoid activity (megestrol acetate).3, 7
In fact, Cushing syndrome induced by continuous administration of megestrol
acetate has been reported.8
DYSFUNCTION OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
Subclinical functional abnormalities of the hypothalamic-pituitary-adrenal
(HPA) axis are much more prevalent than clinical manifestations of these disturbances.
Basal serum cortisol levels seem to be higher in patients infected with human
immunodeficiency virus (HIV) than in controls,9-10
with a negative linear correlation between CD4 cell counts and cortisol found
in some,11 but not all,12
studies. This elevation is usually associated with normal levels of 17-deoxysteroids
(ie, corticosterone, deoxycorticosterone, and 18-OH-deoxycorticosterone),
subnormal increase of both 17-deoxysteroids9
and cortisol9, 13-15
in response to cosyntropin, and an altered circadian rhythm of pituitary and
adrenocortical hormone secretion.10, 16
These patients also have a normal suppression of cortisol synthesis by dexamethasone,
and lower levels of corticotropin10 and dehydroepiandrosterone
(DHEA),10-12,17
an adrenal androgen that has a positive correlation with CD4 cell counts.11-12,17
Although basal aldosterone levels tend to be lower in HIV-infected individuals,
and both hyporeninemic and hyperreninemic hypoaldosteronism have been reported,18 response of plasma aldosterone to angiotensin III
infusion and postural stimulation was normal in a study9;
these findings have been interpreted as a preferential involvement of the
zona fasciculata over the zona glomerulosa.2-3,5
There are 2 case reports of primary aldosteronism in HIV-infected patients,19 perhaps mediated through a reninlike activity of
the HIV aspartic protease, but the causal relationship is far from clear.
PATHOGENESIS
Several pathogenic mechanisms have been proposed to explain the relative
hypercortisolemia present in untreated HIV-positive individuals. First, the
shift of steroid metabolism from aldosterone, DHEA, and 17-deoxysteroids to
cortisol may represent an adaptive response to stress.2-3,5-6
Second, the cortisol-binding globulin of HIV-infected patients shows a higher
number of binding sites compared with controls.20
Some authors have also found increased plasma concentrations of cortisol-binding
globulin associated with progression of the disease,21
whereas others found normal levels of cortisol-binding globulin in all HIV
disease stages.22 Third, the increased cortisol
synthesis in the absence of an increase in corticotropin suggests that some
nonpituitary factors derived from infected immune cells, such as interleukin
(IL)-1 and IL-6,10, 23-24
might directly stimulate the adrenal cortex. In patients with hypercortisolemia
and increased corticotropin levels, these abnormalities may result from a
stimulatory effect of cytokines (eg, interferon- , IL-1, IL-2,
and IL-6)25 or the HIV envelope protein gp12026 on the hypothalamic corticotropin-releasing hormone
release. However, patients with advanced HIV disease often have reduced or
blunted pituitary-adrenal responsiveness to corticotropin-releasing hormone
infusion,27 and cases of secondary adrenal
insufficiency with normal corticotropin stimulation tests have been described.28 Fourth, some patients with AIDS have a syndrome of
peripheral cortisol resistance due to acquired abnormalities of the glucocorticoid
receptor (GR), characterized by an increase in GR density and a decrease in
GR affinity for the substrate.29 These individuals
have a high-cortisol, low-corticotropin state with paradoxical Addisonian
features, but it is conceivable that a clinical spectrum exists, ranging from
subclinical alterations to overt adrenal failure. Finally, the HIV vpr gene
product has been reported to act as a GR coactivator in human lymphoid and
muscle-derived cell lines,30 which could result
in an enhanced effect of glucocorticoids on the target cells.
It has been suggested that this pattern of high cortisol and low DHEA
levels could induce a worsening in immune status by shifting the cytokine
production from the so-called TH1 or cellular-type response (interferon- ,
IL-2, and IL-12) to the TH2 or humoral-type response (IL-4, IL-5,
IL-6, and IL-10),31 a hallmark of HIV disease
progression. In fact, cortisol suppresses interferon- and IL-2 production,
favors IL-4 production, and stimulates programmed cell death (apoptosis).31 In this regard, cortisol-resistant AIDS patients
have a type 1 cytokine profile.32 In contrast,
DHEA appears to enhance immune function,12
probably by antagonizing some effects of cortisol on lymphocytes3;
indeed, both decreased concentrations of DHEA33-34
and increased cortisol/DHEA ratio35 are independent
predictors of progression to AIDS in some studies.
EFFECTS OF ANTIRETROVIRAL TREATMENT
How and whether highly active antiretroviral therapy modifies this profile
is largely unknown. Shortly after the release of protease inhibitors (PIs)
for clinical use, disorders in the body adipose tissue distribution, including
truncal obesity, visceral fat deposition, peripheral wasting, breast hypertrophy,
and enlargement of the dorsocervical pad ("buffalo hump"), often associated
with hyperlipidemia, hyperinsulinemia, and insulin resistance, were recognized.36-37 The similarities in their phenotypic
characteristics led some authors to use the term pseudo-Cushing
syndrome to denominate this clinical picture,38
but soon it became clear that, unlike the pseudo-Cushing syndrome seen in
alcoholism or severe depression, the vast majority of PI-treated patients
had normal or slightly elevated cortisol levels in the morning serum or in
the 24-hour urinary determinations, and showed normal dexamethasone suppression
tests.37, 39-42
Due to a number of clinical and laboratory features shared with classic generalized
lipodystrophic syndromes, these changes in fat distribution and metabolic
profile have been commonly referred to as antiretroviral-associated lipodystrophy.
Lately, lipodystrophy has been linked to antiretrovirals other than PIs (eg,
nucleoside-analogue reverse-transcriptase inhibitors) or even to the HIV infection
itself,43 and ascribed to a large array of
pathogenic mechanisms, such as inhibition by the PIs of several host-cell
proteins involved in lipid and carbohydrate metabolism,44
PI-induced subcutaneous adipocyte apoptosis,45
mitochondrial damage attributable to nucleoside-analogue reverse-transcriptase
inhibitors,46 and cytokine dysregulation in
the setting of immune recovery,47 among others.
In a cross-sectional study,48 the serum
steroid hormone concentrations of patients taking highly active antiretroviral
therapy who presented symptoms of lipodystrophy, according to a subjective
clinical score, were compared with those of nonlipodystrophic individuals.
Serum cortisol levels were elevated in patients compared with HIV-negative
controls, but no differences were found between individuals with or without
lipodystrophy. However, serum DHEA levels were significantly lower and cortisol/DHEA
ratio higher in patients with lipodystrophy, and cortisol/DHEA ratio correlated
positively with both dyslipidemia and the subjective clinical score. Christeff
et al48 speculated that the increased cortisol
and decreased DHEA concentrations were due to the effect of PIs on cytochrome
P450 isoforms involved in steroid metabolism, producing an imbalance between
lipolysis and lipogenesis that could account for the peripheral fat loss and
central fat accumulation.48
In another study,49 patients with antiretroviral-related
lipodystrophy, defined by changes in body shape and abdominal computed tomographic
scan findings, were compared with HIV-negative controls for multiple parameters
of the HPA axis; unfortunately, there was no group of untreated HIV-positive
individuals. Lipodystrophic patients showed normal values of serum cortisol
levels, cortisol response after corticotropin-releasing hormone stimulation,
cortisol-binding globulin concentration, and GR number and affinity, ruling
out hyperactivity of the HPA axis as a cause of lipodystrophy. However, basal
and corticotropin-releasing hormone–stimulated plasma corticotropin
concentration, as well as 24-hour urinary 17-OH-corticosteroid concentrations,
were significantly greater, whereas urinary free cortisol excretion was significantly
lower in patients than in controls. The authors hypothesized that 1 or more
of the antiretroviral drugs taken by these patients alter the metabolism of
cortisol by enhancing the renal 11-ketosteroid reductase activity or by partially
inhibiting the adrenal 11-hydroxylase. According to this study, lipodystrophy
cannot be attributed to hypercortisolism, and other possible mechanisms, such
as selective changes in the glucocorticoid sensitivity of different adipose
tissue depots, are worth exploring.49 We are
aware of a single study that compared serum cortisol levels in nucleoside-analogue
reverse-transcriptase inhibitor–treated and naive HIV-infected patients,
excluding therefore the effect of PI, and no difference was found between
the 2 groups.50
SUMMARY
Clinically evident adrenal insufficiency constitutes an uncommon event
in HIV infection. When present, it usually involves patients in advanced stages
of the infection, with cytomegalovirus disease or under treatment with drugs
that interfere with cortisol metabolism. Even in this setting, the rate of
adrenal insufficiency is probably lower than 5%. However, adrenal reserve
may be marginal, as suggested by a subnormal response to corticotropin stimulation
tests in many cases, and this diagnosis should be kept in mind whenever a
patient who undergoes stressing conditions, such as infection or trauma, develops
hypotension, profound weakness, untreatable fever, or electrolyte abnormalities.
Basal hypocortisolemia, even asymptomatic, should be treated with lifelong
substitutive glucocorticoids, but cortisol supplementation for only very stressing
situations (eg, surgery) is probably sufficient in patients with normal serum
cortisol levels and corticotropin hyporesponsiveness.
Hypercortisolemia without clinical features suggestive of Cushing syndrome
is frequent enough to not warrant a complete workup of adrenal disease. Antiretroviral-associated
lipodystrophy is usually distinguishable from Cushing syndrome on a clinical
basis. However, if lipodystrophy coexists with marked hypercortisolemia, measurement
of 24-hour free urinary cortisol level and a dexamethasone suppression test
would clarify this issue. The extent to which alterations in the HPA axis
are related to these patients' immune dysfunction, as well as the possible
changes induced by antiretroviral treatment, should be further investigated.
At present, no intervention for these subclinical abnormalities is likely
to be useful.
AUTHOR INFORMATION
Accepted for publication September 6, 2001.
Corresponding author and reprints: Julio Collazos, MD, Section of
Infectious Diseases, Hospital de Galdakao, 48960 Vizcaya, Spain.
From the Section of Infectious Diseases, Hospital de Galdakao, Vizcaya,
Spain.
REFERENCES
| |
1. Bricaire F, Marche C, Zoubi D, Regnier B, Saimot AG. Adrenocortical lesions and AIDS. Lancet. 1988;1:881.
2. Grinspoon SK, Bilezikian JP. HIV disease and the endocrine system. N Engl J Med. 1992;327:1360-1365.
ISI
| PUBMED
3. Hofbauer LC, Heufelder AE. Endocrine implications of human immunodeficiency virus infection. Medicine (Baltimore). 1996;75:262-278.
FULL TEXT
| PUBMED
4. McKenzie R, Travis WD, Dolan SA, et al. The causes of death in patients with human immunodeficiency virus infection:
a clinical and pathologic study with emphasis on the role of pulmonary diseases. Medicine (Baltimore). 1991;70:326-343.
PUBMED
5. Brown LS Jr, Singer F, Killian P. Endocrine complications of AIDS and drug addiction. Endocrinol Metab Clin North Am. 1991;20:655-673.
ISI
| PUBMED
6. Lo JC, Schambelan M. Endocrine disease. In: Dolin R, Masur H, Saag MS, eds. AIDS Therapy. Philadelphia, Pa: Churchill Livingstone; 1999:740-751.
7. Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with
AIDS. Ann Intern Med. 1995;122:843-845.
FREE FULL TEXT
8. Padmanabhan S, Rosenberg AS. Cushing's syndrome induced by megestrol acetate in a patient with AIDS. Clin Infect Dis. 1998;27:217-218.
ISI
| PUBMED
9. Membreno L, Irony I, Dere W, Klein R, Biglieri EG, Cobb E. Adrenocortical function in acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1987;65:482-487.
FREE FULL TEXT
10. Villette JM, Bourin P, Doinel C, et al. Circadian variations in plasma levels of hypophyseal, adrenocortical
and testicular hormones in men infected with human immunodeficiency virus. J Clin Endocrinol Metab. 1990;70:572-577.
FREE FULL TEXT
11. Christeff N, Gherbi N, Mammes O, et al. Serum cortisol and DHEA concentrations. Psychoneuroendocrinology. 1997;22 Suppl 1:S11-S18.
12. Wisniewski TL, Hilton CW, Morse EW, Svec F. The relationship of serum DHEA-S and cortisol levels to measures of
immune function in human immunodeficiency virus-related illness. Am J Med Sci. 1993;305:79-83.
ISI
| PUBMED
13. Raffi F, Brisseau JM, Planchon B, Rémi JP, Barrier JH, Grolleau JY. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS. 1991;5:729-733.
ISI
| PUBMED
14. Abbott M, Khoo SH, Hammer MR, Wilkins EG. Prevalence of cortisol deficiency in late HIV disease. J Infect. 1995;31:1-4.
FULL TEXT
|
ISI
| PUBMED
15. Kumar M, Kumar AM, Morgan R, Szapocznik J, Eisdorfer C. Abnormal pituitary-adrenocortical response in early HIV-1 infection. J Acquir Immune Defic Syndr. 1993;6:61-65.
16. Malone JL, Oldfield EC, Wagner KF, et al. Abnormalities of morning serum cortisol levels and circadian rhythms
of CD4 + lymphocyte counts in human immunodeficiency virus type 1-infected
adult patients. J Infect Dis. 1992;165:185-187.
ISI
| PUBMED
17. de la Torre B, von Krogh G, Svensson M, Holmberg V. Blood cortisol and dehydroepiandrosterone sulphate (DHEAS) levels and
CD4 T cell counts in HIV infection. Clin Exp Rheumatol. 1997;15:87-90.
ISI
| PUBMED
18. Seney FD Jr, Burns DK, Silva FG. Acquired immunodeficiency syndrome and the kidney. Am J Kidney Dis. 1990;16:1-13.
19. Stricker RB, Goldberg DA, Hu C, Hsu JW, Goldberg B. A syndrome resembling primary aldosteronism (Conn syndrome) in untreated
HIV disease. AIDS. 1999;13:1791-1792.
FULL TEXT
|
ISI
| PUBMED
20. Martin ME, Benassayag C, Amiel C, Canton P, Nunez EA. Alterations in the concentrations and binding properties of sex steroid-binding
protein and corticosteroid-binding globulin in HIV + patients. J Endocrinol Invest. 1992;15:597-603.
ISI
| PUBMED
21. Schurmeyer TH, Muller V, von zur Muhlen A, Schmidt RE. Thyroid and adrenal function in HIV-infected outpatients. Eur J Med Res. 1997;2:220-226.
PUBMED
22. Lambert M, Zech F, De Nayer P, Jamez J, Vandercam B. Elevation of serum thyroxine-binding globulin (but not of cortisol-binding
globulin and sex hormone-binding globulin) associated with the progression
of human immunodeficiency virus infection. Am J Med. 1990;89:748-751.
FULL TEXT
|
ISI
| PUBMED
23. Tauveron I, Thieblot P, Laurichesse H. The Cushing syndrome associated with AIDS. Ann Intern Med. 1994;120:620-621.
FREE FULL TEXT
24. Biglino A, Limone P, Forno B, et al. Altered adrenocorticotropin and cortisol response to corticotropin-releasing
hormone in HIV-1 infection. Eur J Endocrinol. 1995;133:173-179.
FREE FULL TEXT
25. Raber J, Sorg O, Horn TF, et al. Inflammatory cytokines: putative regulators of neuronal and neuro-endocrine
function. Brain Res Brain Res Rev. 1998;26:320-326.
FULL TEXT
| PUBMED
26. Costa A, Nappi RE, Polatti F, Poma A, Grossman AB, Nappi G. Stimulating effect of HIV-1 coat protein gp120 on corticotropin-releasing
hormone and arginine vasopressin in the rat hypothalamus: involvement of nitric
oxide. Exp Neurol. 2000;166:376-384.
FULL TEXT
|
ISI
| PUBMED
27. Lortholary O, Christeff N, Casassus P, et al. Hypothalamo-pituitary-adrenal function in human immunodeficiency virus-infected
men. J Clin Endocrinol Metab. 1996;81:791-796.
ABSTRACT
28. Eledrisi MS, Verghese AC. Adrenal insufficiency in HIV infection: a review and recommendations. Am J Med Sci. 2001;321:137-144.
ISI
| PUBMED
29. Norbiato G, Bevilacqua M, Vago T, et al. Cortisol resistance in acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:608-613.
ABSTRACT
30. Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP. The HIV-1 virion-associated protein vpr is a coactivator of the human
glucocorticoid receptor. J Exp Med. 1999;189:51-62.
FREE FULL TEXT
31. Clerici M, Trabattoni D, Piconi S, et al. A possible role for the cortisol/anticortisols imbalance in the progression
of human immunodeficiency virus. Psychoneuroendocrinology. 1997;22 Suppl 1:S27-S31.
32. Norbiato G, Bevilacqua M, Vago T, Taddei A, Clerici M. Glucocorticoids and the immune function in the human immunodeficiency
virus infection: a study in hypercortisolemic and cortisol-resistant patients. J Clin Endocrinol Metab. 1997;82:3260-3263.
FREE FULL TEXT
33. Jacobson MA, Fusaro RE, Galmarini M, Lang W. Decreased serum dehydroepiandrosterone is associated with an increased
progression of human immunodeficiency virus infection in men with CD4 cell
counts of 200-499. J Infect Dis. 1991;164:864-868.
ISI
| PUBMED
34. Mulder JW, Frissen PH, Krijnen P, et al. Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic
human immunodeficiency virus-infected men. J Infect Dis. 1992;165:413-418.
ISI
| PUBMED
35. Clerici M, Bevilacqua M, Vago T, Villa ML, Shearer GM, Norbiato G. An immunoendocrinological hypothesis of HIV infection. Lancet. 1994;343:1552-1553.
FULL TEXT
|
ISI
| PUBMED
36. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin
resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
37. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency
virus type 1 protease inhibitors. Clin Infect Dis. 1998;27:65-67.
ISI
| PUBMED
38. Miller KK, Daly PA, Sentochnik D, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected
patients. Clin Infect Dis. 1998;27:68-72.
ISI
| PUBMED
39. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 1998;351:867-870.
FULL TEXT
|
ISI
| PUBMED
40. Hirsch MS, Klibanski A. What price progress? pseudo-Cushing's syndrome associated with antiretroviral
therapy in patients with human immunodeficiency virus infection. Clin Infect Dis. 1998;27:73-75.
ISI
| PUBMED
41. Gervasoni C, Ridolfo AL, Trifirò G, et al. Redistribution of body fat in HIV-infected women undergoing combined
antiretroviral therapy. AIDS. 1999;13:465-471.
FULL TEXT
|
ISI
| PUBMED
42. Wanke CA. Epidemiological and clinical aspects of the metabolic complications
of HIV infection: the fat redistribution syndrome. AIDS. 1999;13:1287-1293.
FULL TEXT
|
ISI
| PUBMED
43. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:228-237.
ISI
| PUBMED
44. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy,
hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-1883.
FULL TEXT
|
ISI
| PUBMED
45. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated
lipodystrophy. AIDS. 1999;13:2261-2267.
FULL TEXT
|
ISI
| PUBMED
46. Brinkman K, Smeiting JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase
inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related
lipodystrophy. Lancet. 1999;354:1112-1115.
FULL TEXT
|
ISI
| PUBMED
47. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML. Alteration of tumor necrosis factor-alpha T-cell homeostasis following
potent antiretroviral therapy: contribution to the development of human immunodeficiency
virus-associated lipodystrophy syndrome. Blood. 2000;95:3191-3198.
FREE FULL TEXT
48. Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly
active antiretroviral therapy: correlation between dyslipidaemia and steroid
hormone alterations. AIDS. 1999;13:2251-2260.
FULL TEXT
|
ISI
| PUBMED
49. Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected
patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab. 1999;84:1925-1931.
FREE FULL TEXT
50. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving
long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
FULL TEXT
|
ISI
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2002;162(10):1199-1200.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.
Stringer et al.
JAMA 2006;296:782-793.
ABSTRACT
| FULL TEXT
Endocrine Aspects of Cancer Gene Therapy
Barzon et al.
Endocr. Rev. 2004;25:1-44.
ABSTRACT
| FULL TEXT
Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies
Leow et al.
J. Clin. Endocrinol. Metab. 2003;88:1961-1976.
FULL TEXT
|
